Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com

Revive Innovations is proud to partner with Mariyah Bejarano, FNP-C, as part of her Doctor of Nursing Practice (DNP) evidence-based practice project. This 12-week study is evaluating how structured nutrition education combined with GLP-1 therapy impacts long-term weight loss success.
We are accepting applications for 15 participants.
If selected, you'll receive:
Please reach us at reviveinnovations@azrevive.com or (928)228-5742 if you cannot find an answer to your question.
The cost to participate is $150, due on July 31 to reserve your place in the study.
This includes 3 months of 0.25 mg compounded Semaglutide with Cyanocobalamin.
After the first month, participants may choose to remain at 0.25 mg or increase their dose. Dose increases are optional and will result in additional medication costs. There are no hidden fees. No consultation fees.
Application Deadline
July 26
Participant Notification
July 27–30
Selected participants will be contacted by phone, text, or email.
Mandatory Orientation
July 31
Choose one class:
Attendance is required to participate.
To be eligible, participants must:
Your privacy is extremely important to us.
Adults interested in medically supervised weight loss who meet the study requirements.
Yes, as long as you have been off all GLP-1 medications for at least 8 weeks before beginning the study.
Only 15 participants will be accepted.
No. Completing the application does not guarantee selection.
Selected applicants will be contacted between July 27–30.
The study costs $150, which covers 3 months of 0.25 mg compounded Semaglutide with Cyanocobalamin.
Dose increases are optional after the first month.
If you choose to increase your dose, additional medication costs will apply.
You'll receive:
Medication pickups will occur on designated Fridays throughout the study.
Selected participants will receive the pickup schedule.
Each visit includes:
Because this is a structured evidence-based practice project, participants are expected to attend scheduled appointments and complete required evaluations whenever possible.
Yes.
No participant names or identifying information will appear in the project. All information is kept confidential and managed in accordance with HIPAA privacy regulations.
If you are not selected, you're still welcome to schedule a consultation with Revive Innovations to discuss our standard medical weight loss program.

Complete the New Patient Weight Loss Study paperwork below to be considered.
Applications close July 26.
Only 15 participants will be selected.
Peptide therapies at Revive Innovations are compounded medications dispensed only with a patient-specific prescription through a licensed compounding pharmacy. These medications are not FDA-approved products. Availability may change with supplier and regulatory guidance. We do not offer brand-name GLP-1 drugs or compounded “copycat” versions of semaglutide or tirzepatide. Please review your informed consent carefully and follow all dosing instructions.